Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials

2018 ◽  
Vol 27 (11) ◽  
pp. 1301-1309 ◽  
Author(s):  
Majed S. Al Yami ◽  
Osamah M. Alfayez ◽  
Razan Alsheikh
Keyword(s):  
Randomised Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Mixed Treatment Comparison ◽  
Treatment Comparison ◽  
Mixed Treatment ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Randomised Controlled

scholarly journals The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis

PLoS ONE ◽  
2015 ◽  
Vol 10 (6) ◽  
pp. e0126769 ◽  
Author(s):  
Jessica E. Potts ◽  
Laura J. Gray ◽  
Emer M. Brady ◽  
Kamlesh Khunti ◽  
Melanie J. Davies ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Weight Loss ◽  
Meta Analysis ◽  
Mixed Treatment Comparison ◽  
Treatment Comparison ◽  
Mixed Treatment ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Improving Glycemic Control in Type 2 Diabetes Using Mobile Applications and e-Coaching: A Mixed Treatment Comparison Network Meta-Analysis

2021 ◽  
pp. 193229682110101
Author(s):  
Min Kyung Hyun ◽  
Jang Won Lee ◽  
Seung-Hyun Ko ◽  
Jin Seub Hwang
Keyword(s):  
Type 2 Diabetes ◽  
Hba1c Level ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Mixed Treatment Comparison ◽  
Gender Ratio ◽  
Treatment Comparison ◽  
Mixed Treatment

Objectives: This study compared the effectiveness of glycemic control among usual care, care management using a mobile application (app), and management using an app with additional e-coaching for patients with type 2 diabetes mellitus (T2DM) using a mixed treatment comparison (MTC) network meta-analysis (NMA). Methods: A systematic search for published randomized controlled trials (RCTs) was conducted, which included Pubmed, Web of Science, Cochrane Central Register of Controlled Trials, CINAL, Koreamed, KMbase, and ScienceOn, until October 2020. Among the 10,391 studies identified after removing duplicates, 14 RCTs were finally included in the MTC NMA. Data extraction and methodological quality assessment using version 2 of the Cochrane tool for assessing the risk-of-bias in randomized trials (RoB 2) was performed. The comparative efficacy was analyzed using the random-effects NMA based on a frequentist model by the intervention group and main outcome variables. Results: At the 3-month follow-up after each intervention, a comparison of the P-scores revealed the app plus e-coaching intervention to be the most effective method for reducing the HbA1c level in a homogeneous gender ratio group (P-score 0.92). At the 6-month follow-up period, app intervention was the best in reducing the HbA1c level in the homogeneous gender ratio and under 60 years of age group (P-score 1.00). Conclusions: Based on MTC analysis using the data from published RCTs, mobile apps or apps with e-coaching interventions for T2DM patients were more effective in improving the HbA1c values, FBS, and hypoglycemia frequency than usual care. Nevertheless, further research will be needed to clarify the effects of adding e-coaching to the app. Study registration: Research Registry UIN (reviewregistry780)

Sign in / Sign up

Export Citation Format

Share Document